- CohBar Inc And Morphogenesis Inc To Discuss Definitive Merger Agreement Call TranscriptMay 23, 2023
- Q3 2022 CohBar Inc Earnings Call TranscriptNov 08, 2022$2.27 (+2.25%)Earnings
- Q2 2022 CohBar Inc Earnings Call TranscriptAug 15, 2022$5.67 (-0.58%)Earnings
- Q1 2022 CohBar Inc Earnings Call TranscriptMay 16, 2022$5.96 (-3.17%)Earnings
- Q4 2021 CohBar Inc Earnings Call TranscriptMar 29, 2022$9.67 (+4.37%)Earnings
- Q3 2021 CohBar Inc Earnings Call TranscriptNov 15, 2021$19.8 (-5.32%)Earnings
- CohBar Inc at H C Wainwright NASH Investor Conference (Virtual) TranscriptOct 12, 2021
- Q2 2021 CohBar Inc Earnings Call TranscriptAug 10, 2021$38.7Earnings
- Q1 2021 CohBar Inc Earnings Call TranscriptMay 17, 2021$36.6 (+1.67%)Earnings
- Q4 2020 CohBar Inc Earnings Call TranscriptMar 30, 2021$37.8 (-4.55%)Earnings
- Q3 2020 CohBar Inc Earnings Call TranscriptNov 16, 2020$34.5 (+5.50%)Earnings
- CohBar, Inc. - Special Call TranscriptNov 06, 2020
- Q2 2020 CohBar Inc Earnings Call TranscriptAug 13, 2020$45.6 (-1.94%)Earnings
- CohBar, Inc. - Special Call TranscriptJun 16, 2020
- CohBar Inc Annual Shareholders Meeting TranscriptJun 16, 2020
- Q1 2020 CohBar Inc Earnings Call TranscriptMay 14, 2020$71.4 (-12.50%)Earnings
- Q4 2019 CohBar Inc Earnings Call TranscriptMar 12, 2020$43.8 (-17.05%)Earnings
- Q3 2019 CohBar Inc Earnings Call TranscriptNov 06, 2019$57 (-7.77%)Earnings
- Q2 2019 CohBar Inc Earnings Call TranscriptAug 07, 2019$42.6 (-0.70%)Earnings
- CohBar, Inc. Investor Update TranscriptJun 18, 2019
- CohBar Inc Annual Shareholders Meeting TranscriptJun 18, 2019
- Q1 2019 CohBar Inc Earnings Call TranscriptMay 07, 2019$84.3 (+2.93%)Earnings
- CohBar, Inc. - Special Call TranscriptMay 02, 2019
- Q4 2018 CohBar Inc Earnings Call TranscriptMar 18, 2019Earnings
CohBar, Inc. - Special Call Transcript
Good afternoon, and welcome to the CohBar KOL call. (Operator Instructions) As a reminder, this conference is being recorded, and a replay will be made available on the CohBar website following the event.
I'd now like to turn the call over to your host, Steve Engle, Chief Executive Officer of CohBar. Please go ahead, sir.
Thank you, Sarah. Welcome, everyone. Thank you for joining us. CohBar is developing compounds based on breakthrough mitochondrial science that represents a major new source of therapeutics for multiple diseases. Today, we are very pleased to discuss our novel Antifibrotic Peptides for IPF and other fibrotic diseases. And with the help of Dr. Maher, who is a world-class medical expert and clinical trialist, the need for new approaches in idiopathic pulmonary fibrosis.
Next slide, please. Forward-looking statements apply.
Next slide, please. CohBar is the leader in developing a new class therapeutics -- mitochondrial-based therapeutics. Our Chief Science Officer, Ken
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)